Alphatec Holdings, INC

Alphatec Holdings announced the approval of its 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan by stockholders at its annual meeting.

Alphatec Holdings announced a new $300 million senior secured credit agreement, including a $175 million term loan and a $125 million revolving credit facility, to refinance existing debt and support future growth.

Alphatec Holdings, Inc. announced the retirement of Director Ward W. Woods, effective February 27, 2026, with his remaining unvested restricted stock units immediately vesting.

Alphatec Holdings, Inc. announced robust full-year 2025 financial results, including 25% revenue growth and a pivotal shift to positive free cash flow, alongside an optimistic 2026 outlook.

Alphatec Holdings, Inc. announced preliminary unaudited financial results for 2025, showing significant revenue growth, and provided a positive financial outlook for 2026, alongside acquiring exclusive distribution rights for a next-generation biologic.

Alphatec Holdings, Inc. announced with deep sadness the passing of Jeffrey P. Rydin, a long-serving and influential member of its Board of Directors.

Alphatec Holdings, Inc. (ATEC) filed its Form 10-Q for the quarter ended June 30, 2026, detailing a 15% increase in revenue driven by product volume and portfolio expansion, alongside significant debt management activities.

Alphatec Holdings reported a 14% increase in revenue for Q1 2026, reaching $192.1 million, but also saw its net loss widen to $33.9 million.

Alphatec Holdings, Inc. reported a 30% increase in third-quarter revenue and a significant reduction in net loss, driven by strong product adoption and strategic debt refinancing.

Alphatec Holdings, a medical technology company, announced a 27% increase in Q2 2025 revenue and a significant positive swing in operating cash flow, driven by product adoption and market share expansion, while strategically refinancing its debt.

Alphatec Holdings announces a 22% increase in revenue for Q1 2025, driven by product volume growth and strategic financial maneuvers including a convertible notes offering and debt repurchase.

Alphatec Holdings, a medical technology company focused on spinal disorders, announced a 27% increase in revenue for the third quarter of 2024, while still experiencing net losses.

Alphatec Holdings, Inc. announced a 25% increase in total revenue to $764.2 million for the fiscal year ended December 31, 2025, driven by surgeon adoption and product portfolio expansion.

Alphatec Holdings' 2024 annual report reveals a 27% revenue increase, driven by surgeon adoption of its innovative spine surgery technologies.

Alphatec Holdings, a medical technology company focused on spine disorders, announced a 37% increase in revenue for the year ended December 31, 2023, reaching $482.3 million.

Director Karen McGinnis acquired 32,012 restricted stock units and sold 6,050 shares to cover tax obligations.

Director Quentin S. Blackford was granted 32,012 restricted stock units by Alphatec Holdings, Inc. on June 10, 2026.

Alphatec Holdings director Keith Valentine was granted 32,012 restricted stock units as part of a standard equity compensation arrangement.

Director David R. Pelizzon was granted 32,012 restricted stock units by Alphatec Holdings, Inc. on June 10, 2026.

Director David M. Demski was granted 32,012 restricted stock units by Alphatec Holdings, Inc. on June 10, 2026.

Alphatec Holdings director Mortimer Berkowitz III was granted 32,012 restricted stock units as part of his compensation.

Alphatec Holdings issues a supplement to its proxy statement clarifying that brokers have discretionary voting authority on Proposal 4, which seeks to increase the number of authorized shares.

Alphatec Holdings will hold its annual stockholders meeting on June 11, 2025, to vote on key proposals including the election of directors, ratification of the auditor, and amendments to the equity incentive plan and certificate of incorporation.

Alphatec Holdings is asking stockholders to vote on the election of directors, ratification of the accounting firm, amendments to the equity incentive plan and certificate of incorporation, and executive compensation at the upcoming annual meeting.

Alphatec Holdings will hold its annual stockholders meeting on June 12, 2024, to vote on director elections, auditor ratification, and executive compensation.

Alphatec Holdings will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, to vote on director elections, auditor ratification, and executive compensation.

An insider group, including Squadron Capital LLC and Jennifer N. Pritzker, has reduced its beneficial ownership in Alphatec Holdings, Inc. through recent open market sales.

L-5 Healthcare Partners, LLC and Paul Segal have reduced the exercise price of their Alphatec Holdings, Inc. warrant to $0.01 per share as part of a litigation settlement, resulting in their beneficial ownership falling below 5%.

L-5 Healthcare Partners, LLC and Paul Segal have filed an Amendment No. 9 to their Schedule 13D, reporting a continued beneficial ownership of 5.3% in Alphatec Holdings, Inc.

L-5 Healthcare Partners, LLC and Paul Segal have filed an Amendment No. 8 to their Schedule 13D, revealing a 6.45% beneficial ownership stake in Alphatec Holdings, Inc.